This leads to a decrease in SNF5 tumour suppressor which is linked to promotion of hereditary leiomyomatosis and renal cell carcinoma (HLRCC) [40, 41]. Here, SMARCB1 is linked to hereditary leiomyomatosis and renal cell cancer.